CIMZIA (certolizumab pegol) Patient Assistance Program
Don’t let the high cost of brand specialty anti-TNF biologic therapy disrupt your treatment. We help eligible patients access Cimzia (certolizumab pegol) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Cimzia (certolizumab pegol) is FDA-approved for moderately-to-severely active Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis. It is a PEGylated anti-TNF Fab fragment given as a subcutaneous injection.
- Without assistance, Cimzia costs commonly run approximately $5,000–$6,000 per monthly maintenance dose, with annual costs commonly $60,000–$72,000+.
- Through AffordMyPrescriptions, qualifying patients can access Cimzia for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Cimzia in the U.S. as of 2026. Other TNF inhibitors include adalimumab (Humira, with multiple biosimilars at lower cost), infliximab (Remicade, with multiple biosimilars), etanercept (Enbrel), and golimumab (Simponi). Cimzia is unique among TNF inhibitors for its minimal placental transfer — making it often preferred during pregnancy.
What Is Cimzia Prescription Assistance Program?
The Cimzia Prescription Assistance Program is a manufacturer-sponsored initiative that provides Cimzia at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for inflammatory conditions in patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, rheumatology/dermatology/gastroenterology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Cimzia costs roughly $5,000–$6,000 per month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$5,800 | Save ~$5,730/mo |
| CVS Pharmacy | ~$6,000 | Save ~$5,930/mo |
| Walmart | ~$5,200 | Save ~$5,130/mo |
| Costco | ~$5,100 | Save ~$5,030/mo |
Specialty Pharmacy | ~$5,400 | Save ~$5,330/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Cimzia Prescription Program?
The Patient Assistance Program is free to apply for and provides Cimzia at no medication cost if approved. Our $69.95/month service covers full advocacy. With TNF biosimilars for adalimumab and infliximab widely available at lower cost, we’ll help your prescriber determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Cimzia:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
- Still $5,000–$6,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Cimzia assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Cimzia Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Cimzia:
Cimzia (certolizumab pegol) is a PEGylated humanized antibody Fab fragment that binds and neutralizes tumor necrosis factor alpha (TNF-α) — a master inflammatory cytokine driving rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and psoriasis. Cimzia is unique among TNF inhibitors for its structure (Fab fragment, no Fc) and minimal placental transfer.
How Cimzia Works:
Certolizumab pegol is a specialized TNF-α inhibitor consisting of an antibody Fab fragment chemically linked to polyethylene glycol (PEG), which neutralizes the master inflammatory cytokine TNF-α. The attached PEGylation extends the drug’s half-life, allowing for convenient monthly dosing. Crucially, because it lacks an Fc region, it does not actively cross the placenta via the FcRn receptor. This unique structural feature results in the lowest fetal exposure among TNF inhibitors, making it a preferred choice for patients of childbearing potential.
Form and use:
Cimzia is administered via subcutaneous injection and is available as either prefilled syringes or a lyophilized powder requiring reconstitution. The standard dosing regimen begins with a loading phase of 400 mg at weeks 0, 2, and 4, followed by a maintenance dose of 400 mg every 4 weeks or 200 mg every 2 weeks. After receiving proper training, patients can safely self-inject the medication at home. However, undergoing a tuberculosis (TB) screening is strictly required before starting the treatment.
Generic availability:
As of 2026, there is no biosimilar generic version of Cimzia available in the United States. While other TNF inhibitors like adalimumab and infliximab have multiple lower-cost biosimilars on the market, Cimzia, etanercept, and golimumab currently do not. Because biosimilars offer a substantially lower cost, switching from Cimzia to an available TNF biosimilar may provide significant financial savings for many patients.
Warnings:
Cimzia carries a Boxed Warning for serious infections—including TB reactivation, invasive fungal infections, bacterial sepsis, and viral reactivations—as well as malignancies like lymphoma. Additional warnings include the exacerbation of heart failure, demyelinating disease (meaning it should be avoided in MS), and lupus-like syndrome. Patients must also watch for hypersensitivity reactions, hematologic events, and ensure they avoid receiving live vaccines while on this medication.
FAQ (Frequently Asked Questions)
How Much Does Cimzia Cost Without Insurance?
Cimzia costs approximately $5,000–$6,000 per month. Annual costs commonly $60,000–$72,000+. Through AffordMyPrescriptions, qualifying patients receive Cimzia at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Cimzia Different From Humira Or Remicade?
All three are TNF inhibitors. Cimzia is a PEGylated Fab fragment (no Fc region) — subcutaneous every 2 or 4 weeks. Humira (adalimumab) is a full IgG1 antibody — subcutaneous every 1 or 2 weeks, with multiple biosimilars now available at lower cost. Remicade (infliximab) is a full IgG1 antibody — IV every 8 weeks, with multiple biosimilars. Cimzia’s lack of Fc region means minimal placental transfer — often making it the preferred TNF inhibitor during pregnancy.
Why Is Cimzia Preferred During Pregnancy?
Maternal IgG antibodies are actively transported across the placenta to the fetus via the FcRn receptor in the second and third trimesters. Certolizumab pegol lacks an Fc region, so it does NOT engage FcRn and shows minimal placental transfer (cord blood levels are <5% of maternal levels in studies). This makes Cimzia the preferred TNF inhibitor for patients of childbearing potential — particularly in the third trimester. Other TNF inhibitors (Humira, Remicade, Enbrel) cross the placenta in substantial amounts in the second and third trimesters.
Why Do I Need TB Testing Before Cimzia?
NF inhibitors can reactivate latent tuberculosis. TB screening (PPD or QuantiFERON-Gold) is required before starting. Patients with positive screening typically need TB prophylaxis (isoniazid or rifapentine-isoniazid) before or alongside Cimzia.
Are TNF Biosimilars An Option?
Yes, but biosimilars exist for adalimumab (Humira) and infliximab (Remicade) — not certolizumab. If your insurance prefers a TNF biosimilar over Cimzia, switching to an adalimumab biosimilar (Hyrimoz, Cyltezo, Yusimry, Amjevita) or an infliximab biosimilar (Inflectra, Renflexis) at substantially lower cost may be a reasonable alternative. The key Cimzia advantage that biosimilars don’t replicate is the minimal placental transfer during pregnancy.
Can I Get Cimzia Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to a TNF biosimilar at substantially lower cost (adalimumab biosimilars, infliximab biosimilars), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Arthritis Foundation, Crohn’s & Colitis Foundation, National Psoriasis Foundation, Spondylitis Association, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Cimzia, our team may be able to help you access assistance programs designed to make brand specialty TNF inhibitor therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.